

To: Thayer, Kris[thayer.kris@epa.gov]; Yamada, Richard (Yujiro)[yamada.richard@epa.gov]; Kavlock, Robert[Kavlock.Robert@epa.gov]; Rodan, Bruce[rodan.bruce@epa.gov]; Sjogren, Mya[Sjogren.Mya@epa.gov]; Plotkin, Viktoriya[Plotkin.Viktoriya@epa.gov]; Gwinn, Maureen[gwinn.maureen@epa.gov]; Bahadori, Tina[Bahadori.Tina@epa.gov]; D'Amico, Louis[DAmico.Louis@epa.gov]
From: Vandenberg, John
Sent: Fri 6/23/2017 2:00:02 PM
Subject: Chloroprene : Followup to chloroprene briefing and contact with OAQPS and R6
[Chloroprene Background Info 6_22_17.docx.docx](#)
[Responses to 1st Interagency Comments 08202009.doc](#)
[CHLOROPRENE OMB IASD COMMENTS.PDF](#)
[Letter to IRIS - Chloroprene 06222017.pdf](#)

Followup to yesterday's briefing on chloroprene:

- 1) Summary and details regarding chloroprene IRIS assessment, and NTP study details (with thanks to Allen Davis). (file: Chloroprene Background Info 6_22_17)
 - a. Note that the statistical significance of the epidemiological studies is summarized
 - b. Note that the dose groups from the NTP are included
 - c. Note that the modeling of multiple tumors is presented
 - d. Appendix A of the linked Chloroprene Toxicological Review includes peer review and public comments, and EPA responses
- 2) OMB comments on Draft IRIS Tox Review (prior to peer review) (file: Responses to 1st Interagency Comments 08202009.doc)
 - a. The OMB comments were provided by Nancy Beck
- 3) OMB comments on Final IRIS Tox Review (post-peer review) (file: Chloroprene_OMB_IASD_Comments.pdf)
- 4) Evaluation of cancer rates in zip codes nearest Denka facility, provided by consultant to OECA (Letter to IRIS - Chloroprene 06222017.pdf)

Contact with R6 and OAQPS:

-

I spoke with David Gray (R6 deputy RA) and Erika Sasser and Kelly Rimer (OAQPS DD and

BC involved in NATA) late yesterday about our chloroprene/Denka discussion. They all have the briefing material used yesterday. I shared my view that the briefing was informative and useful in developing the plan to coordinate with OCSPP/Nancy Beck and meet with the Denka reps next week.

David was very appreciative of the ORD assistance and was comfortable with the plan to meet with Denka to listen to their concerns about the chloroprene IRIS assessment. Similar for Erika and Kelly. They understand the context for the potential Request for Correction and our evaluation of the evidence used in the IRIS assessment as well as the newly published studies. I thanked OAQPS for their help with preparing the briefing materials.